Compare LVWR & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVWR | ELDN |
|---|---|---|
| Founded | 2022 | 2004 |
| Country | United States | United States |
| Employees | 151 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 291.8M |
| IPO Year | N/A | 2014 |
| Metric | LVWR | ELDN |
|---|---|---|
| Price | $0.85 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 330.5K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $619.07 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $1.35 |
| 52 Week High | $6.44 | $4.60 |
| Indicator | LVWR | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 42.16 | 52.50 |
| Support Level | N/A | $3.69 |
| Resistance Level | $1.28 | $4.15 |
| Average True Range (ATR) | 0.12 | 0.23 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 33.43 | 41.58 |
LiveWire Group Inc is an all-electric vehicle company. It sells electric vehicles and related parts and accessories and apparel in the United States and certain international markets. The company's segment includes Electric Motorcycles and STACYC. Electric Motorcycles segment sells electric motorcycles, related parts and accessories and apparel in the United States and certain international markets; STACYC segment sells electric balance bikes for kids, related parts and accessories and apparel in the United States and certain international markets. LiveWire generates revenue from the sale of electric motorcycles, Parts, accessories and apparel. Majority of revenue is from USA.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.